Tag:

Type 1 diabetes

Latest Headlines

Latest Headlines

EC adds Cellnovo to R&D project to add artificial intelligence in Type 1 diabetes management

Cellnovo Group is already part of a major NIH trial for an artificial pancreas that incorporates its connected insulin pump-blood glucose monitor. Now, it's joining a European Commission-sponsored R&D project to develop new technology aimed at Type 1 diabetics.

Medtronic artificial pancreas may hit the market next spring, as pivotal trial nears final data

An artificial pancreas, a device that automatically regulates insulin dosage for Type 1 diabetes patients based on real-time glucose data, may be a reality soon. Medtronic is nearing final data for a pivotal trial of its Hybrid Closed Loop System. It reportedly expects to submit to FDA for approval by the end of June, with an anticipated launch by April 2017.

Scientists create insulin-producing patch made with beta cells to replace insulin injection

In the last few years, researchers have gotten very good at mass-producing pancreatic beta cells that produce sufficient insulin to offer improvement for diabetic patients. But now, they're focused on inventing and testing the means to use these beta cells in a way that effectively introduces insulin into the system--while simultaneously protecting the cells from a patient's immune system.

Dexcom integrates its latest CGM into the Apple Watch

Diabetics could already access data from their Dexcom G5 Mobile Continuous Glucose Monitor via the Health App on their iPhone. Now they can do so on the Apple Watch too. Even without actually opening the app, users can quickly glance at their CGM data on their Apple Watch or on an iPhone.

Eli Lilly reports promising early-stage results for its fast-acting insulin formulation

Eli Lilly reported strong Phase I results of its BioChaperone Lispro ultrarapid formulation of insulin, which it in-licensed from Lyon, France's Adocia for $50 million upfront and up to $520 million in milestone payments. The candidate is designed to enable injections before, during or after meals due to its fast-acting nature.

Cellnovo partners with TypeZero in major NIH-backed artificial pancreas trial in Type 1 diabetics

Paris-based Cellnovo Group has partnered with TypeZero Technologies to be part of a previously announced clinical trial of an artificial pancreas that's being backed by a $12.8 million grant from the U.S. National Institutes of Health. Cellnovo's connected insulin patch pump will be used in conjunction with TypeZero's inControl AP software and a Dexcom continuous glucose monitor to form the whole of the artificial pancreas system being tested.

NIH backs smartphone-based artificial pancreas trials with almost $13M

The U.S. National Institutes of Health is financing what's expected to be the largest long-term clinical study for an artificial pancreas to regulate the blood sugar levels in Type 1 diabetics to the tune of $12.7 million. This is the biggest chunk it's yet doled out as part of a program the agency started in 2014 to promote testing of artificial pancreas systems that's already backed at least three other research efforts.

JDRF, ADA redefine Type 1 diabetes framework to encourage early diagnosis, prevention

In an effort aimed at encouraging earlier diagnosis and even potentially prevention for Type 1 diabetes, the JDRF and the American Diabetes Association have published a new evaluation of the presymptomatic staging of Type 1 diabetes.

DexCom ups 2015 guidance but doesn't aim for profit; plans next-gen launches this year, in 2017

DexCom made a big splash last quarter when it launched a marketing campaign featuring teen pop idol Nick Jonas, who has Type 1 diabetes. The move to address its significant pediatric market helped the connected continuous glucose monitor company to new revenue heights--up 59% to $93.2 million in the second quarter as compared to a year ago.

Study: Researchers find dual-hormone artificial pancreas best for treating nocturnal hypoglycemia

Canadian researchers have found that the dual-hormone artificial pancreas works best for treating patients with Type 1 diabetes by reducing the amount of time they are exposed to nocturnal hypoglycemia.